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Abstract
Objectives: The magnitude of HIV viral rebound following ART cessation has consequences for clinical outcome and onward
transmission. We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV
infection (CHI).
Design: Two populations with protocol-indicated ART cessation from SPARTAC (PHI, n = 182) and SMART (CHI, n = 1450)
trials.
Methods: Time for pVL to reach pre-ART levels after stopping ART was assessed in PHI using survival analysis. Differences in
pVL between PHI and CHI populations 4 weeks after stopping ART were examined using linear and logistic regression.
Differences in pVL slopes up to 48 weeks were examined using linear mixed models and viral burden was estimated
through a time-averaged area-under-pVL curve. CHI participants were categorised by nadir CD4 at ART stop.
Results: Of 171 PHI participants, 71 (41.5%) rebounded to pre-ART pVL levels, at a median of 50 (95% CI 48–51) weeks after
stopping ART. Four weeks after stopping treatment, although the proportion with pVL$400 copies/ml was similar (78% PHI
versus 79% CHI), levels were 0.45 (95% CI 0.26–0.64) log10 copies/ml lower for PHI versus CHI, and remained lower up to 48
weeks. Lower CD4 nadir in CHI was associated with higher pVL after ART stop. Rebound for CHI participants with CD4 nadir
.500 cells/mm3 was comparable to that experienced by PHI participants.
Conclusions: Stopping ART initiated in PHI and CHI was associated with viral rebound to levels conferring increased
transmission risk, although the level of rebound was significantly lower and sustained in PHI compared to CHI.
Citation: Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, et al. (2012) Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART
Commenced in Primary and Chronic HIV Infection. PLoS ONE 7(8): e43754. doi:10.1371/journal.pone.0043754
Editor: Bruno Verhasselt, Ghent University, Belgium
Received April 9, 2012; Accepted July 26, 2012; Published August 31, 2012
Copyright:  2012 Hamlyn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding provided by Wellcome Trust grants WT069598MA and 069598/Z/02/B. The Biomedical Research Centre provided staff and infrastructure
support in the United Kingdom. The SMART trial was funded by National Institute of Health Grants U01-AI068641, U01-AI046362 and U01-AI042170. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JO is a PLoS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and
materials. No other conflict of interest is declared.
* E-mail: e.hamlyn@nhs.net
Introduction
Long-term use of antiretroviral therapy (ART) in HIV-positive
persons may be challenged by the need for high-level adherence,
development of drug resistance, toxicities, and cost. Treatment
strategies conferring durable virological control, whilst minimising
ART exposure are highly desirable. With this goal in mind,
strategic interruption of ART was the focus of several studies [1–
3].
However, interruption of ART is no longer a recommended
strategy [2] and the level of HIV plasma viral load (pVL) following
ART stop has been shown to reach levels comparable to pre-
treatment values [2–4], increasing onward transmission risk [5].
Inaccessible reservoirs of latently-infected resting memory CD4 T-
cells are hypothesised to be the major source contributing to
viraemia rebound after stopping ART [6,7].
Recent research has shown the dramatic effect of ART to
prevent onward viral transmission [8], and mathematical models
predict that it may potentially be possible to eliminate HIV
infection at a population level with universal treatment coverage
for all HIV-positive individuals, irrespective of CD4 count [9].
However, although not recommended, consideration of the
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potential impact of individuals choosing to stop ART could be
considerable, and data are needed on subsequent viral rebound to
better inform future transmission models. Furthermore, final
results from SPARTAC suggested that ART initiated in primary
HIV infection (PHI) was associated with a change in pVL set-point
out to 60 weeks after stopping therapy [10] whilst the SMART
trial reported that interruption of ART in chronic infection (CHI)
was associated with an increased risk of all-cause mortality
The level of viral rebound following interruption of ART
commenced in at different stages of HIV infection is, therefore,
highly relevant from both a clinical and public health perspective
and warrants further investigation.
We, therefore, wanted to compare the pVL changes observed
after cessation of ART initiated in chronic HIV infection with
those in PHI by comparing viral rebound between individuals
enrolled in two protocol-indicated ART interruption studies;
SPARTAC and SMART.
Methods
Ethics statement
The SPARTAC trial was approved by the following authorities:
Medicines and Healthcare products Regulatory Agency (UK),
Ministry of Health (Brazil), Irish Medicines Board (Ireland),
Medicines Control Council (South Africa), and the Uganda
National Council for Science and Technology (Uganda). It was
also approved by the following ethics committees in the
participating countries: Central London Research Ethics Com-
mittee (UK), Hospital Universita´rio Clementino Fraga Filho
Ethics in Research Committee (Brazil), Clinical Research and
Ethics Committee of Hospital Clinic in the province of Barcelona
(Spain), The Adelaide and Meath Hospital Research Ethics
Committee (Ireland), University of Witwatersrand Human Re-
search Ethics Committee, University of Kwazulu-Natal Research
Ethics Committee and University of Cape Town Research Ethics
Committee (South Africa), Uganda Virus Research Institute
Science and ethics committee (Uganda), The Prince Charles
Hospital Human Research Ethics Committee and St Vincent’s
Hospital Human Research Ethics Committee (Australia), and the
National Institute for Infectious Diseases Lazzaro Spallanzani,
Institute Hospital and the Medical Research Ethics Committee,
and the ethical committee Of the Central Foundation of San
Raffaele, MonteTabor (Italy). The INSIGHT SMART trial was
approved by the University of Minnesota institutional review
board. All participants signed a written informed consent.
Study populations
Viral dynamics following treatment interruption were compared
using data from SPARTAC and SMART participants. SPAR-
TAC is an international RCT comparing no therapy, 12-week
ART, or 48-week ART initiated within a maximum of 6 months
from the last documented HIV negative test date. The primary
outcome measure was time to confirmed CD4 cell count ,350
cells/mm3, or the initiation of long-term therapy. PHI was
identified according to the trial protocol. The trial recently
reported a significant difference in time to the primary endpoint
for the 48-week, but not the 12-week, ART arm compared to no
therapy, although not significantly longer than the time already
spent on therapy [10]. SMART is an international RCT which
compared a CD4-guided strategy of planned treatment interrup-
tions versus continuous ART in chronically HIV-infected individ-
uals. Eligible participants with CD4.350 cells/mm3 were
randomised to either a Drug Conservation (DC) or Viral
Suppression (VS) arm. Enrolment was stopped on 11th January
2006 and participants in the DC arm were recommended to re-
initiate ART as interim results clearly indicated superiority of the
VS arm [2].
Individuals were included in this analysis if they underwent
protocol-indicated ART cessation, i.e. on ART at time of
randomisation to the DC arm in SMART (hereafter, the
chronically-infected population) or randomised to one of the two
treatment arms in SPARTAC (hereafter, the PHI population), and
had a CD4 cell count and pVL available at the time of ART stop.
Subsequent pVL measurements were scheduled at 4, 12, 24, 36,
48 and 4, 8, 16, 32, 40, 48 weeks after ART stop in SPARTAC
and SMART respectively. pVLs were determined locally; for
included participants, 40, 59, ,1 and ,1% from SPARTAC and
20, 74, 4 and 2% from SMART were measured using bDNA,
PCR, NASBA and other assays, respectively.
Statistical methods
We examined the time following ART stop for pVL to reach
pre-ART levels in the PHI population, using survival methods. We
then compared pVL levels at 4 weeks after stopping ART in the
PHI participants, and up to 48 weeks afterwards, with those in
chronically-infected individuals. Using linear and ordered logistic
regression, respectively, we examined differences in absolute levels
and in the proportions with pVL,400, 400–3499, 3500–9999,
10,000–49,999 or $50,000 copies/ml at 4 weeks after ART stop
[5]. Using linear mixed models, we examined differences in pVL
levels and slopes over 4–48 weeks after ART stop, and estimated
predicted pVLs at 4 and 36 weeks after ART stop for
representative PHI and chronically-infected participants (male
infected through sex with men, aged 40 years and with CD4 600
cells/mm3 at ART stop). We estimated the complete viral burden,
through a time-averaged area–under-pVL curve, over the whole
period after stopping ART. We then categorised the chronically-
infected participants according to their nadir CD4 count at ART
stop in order to assess whether any differences over 48 weeks
between the populations could be explained solely by nadir CD4.
Follow-up began from the date of first stopping all drugs in the
ART regimen and was censored at the last pVL measurement, the
48 week visit, when ART was re-initiated, or 11th January 2006 for
SMART participants, whichever was earliest.
We restricted analyses to participants who had suppressed pVL
to,400 copies/ml at the time of ART stop, as this was the limit of
the least sensitive assay used across both trials. pVL data were
log10-transformed and values ,400 copies/ml were treated as
= 400 copies/ml for all participants to avoid confounding by trial,
as a greater proportion of pVLs were measured using this
detection limit in the PHI compared to chronically-infected
participants (13 versus 6% ,400 copies/ml and 9 vs. 16%,
respectively, ,50 copies/ml). CD4 and pVL at ART stop were
defined by those closest to ART stop (up to 24 and 12 weeks
before, respectively, and no more than 2 weeks after). Subsequent
pVLs were defined by those closest to the scheduled visits (allowing
a +/22 week window around the week 4 and 6 visits and a +/24
week window around subsequent visits). Pre-ART pVLs in PHI
participants were estimated as the mean of all available pVLs
before ART initiation (9%, 85%, 5%, 1% participants had 1, 2, 3
and 4 pre-ART pVLs available, respectively). We also restricted
analyses to include sexually-infected individuals only as few were
from other risk groups in the PHI population.
Models were adjusted for the effect of sex/risk group (sex
between men (MSM), heterosexual men or heterosexual women),
age and CD4 at ART stop. No adjustments were made for time on
ART, as this is confounded by duration of infection and, therefore,
by trial, nor for ART class (also confounded by trial). Using only
HIV Viral Rebound after ART Stop
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data from the chronic population, however, we investigated the
possible effect of ART class on viral rebound. We also investigated
whether there were differences in the effects of participant
characteristics at ART stop for PHI compared to chronically-
infected participants, and CD4 nadir up to ART stop, where
appropriate, using interactions.
As SMART participants were enrolled into the trial with
prevalent HIV infection, duration of HIV infection and time since
first initiation of ART may not have been known and so reported
values should be regarded as best estimates. In particular, the
duration of infection is based on first known HIV positive result,
therefore, the intervals are likely to be underestimates.
Results
Description of the population
Of the 243 SPARTAC participants randomised to one of the
two treatment arms, 16 were excluded because they did not
initiate ART (n = 5), did not stop ART (n = 6), were on ART for
,15 days (n = 4) or did not have a pVL at ART stop (n = 1). Of
the 2290 SMART participants on ART at the time of
randomisation to the DC arm, 256 were excluded because they
did not stop ART (n = 42, 25 of whom were randomised in the
month prior to 11th January 2006), stopped ART after 11th
January 2006 (n = 20), did not have a pVL at ART stop (n = 1) or
did not have any subsequent pVLs after stopping ART (n = 193,
153 of whom only stopped in the month prior to 11th January
2006). Additional exclusions were as follows: 43 SPARTAC and
384 SMART participants with pVL$400 copies/ml at ART stop,
125 SMART participants with reported risk group IDU, and 2
SPARTAC and 75 SMART participants with other/unknown
route of HIV transmission. Therefore, 182 PHI and 1450
chronically-infected participants were included in our analyses.
Participant demographics, ART exposure and CD4 at time of
treatment discontinuation are shown in Table 1. Compared to
those chronically-infected, PHI participants were younger (median
34 versus 44 years), more likely to be female (33% versus 24%),
had considerably less ART exposure (6% versus 44% ever exposed
to $3 drug classes) and were more likely to be on a protease
inhibitor regimen at the time of ART stop (94% versus 36%). At
ART stop, median CD4 was slightly higher among PHI compared
to chronically-infected participants (707 versus 646 cells/mm3).
Among chronically-infected participants, 76% had nadir
CD4,350 cells/mm3. Five-hundred and fifty-nine (39%) chron-
ically-infected participants were censored on 11th January 2006
due to discontinuation of the SMART DC arm. A further 17 (9%)
PHI and 463 (32%) chronically-infected participants were
censored before their 48 week visit due to ART re-initiation.
The median (IQR) follow-up was 48 (45, 49) and 27 (12, 43) weeks
for the PHI and chronically-infected participants, respectively, and
the median (IQR) number of RNA measurements included per
individual was 6 (5, 6) and 4 (3, 6), respectively.
Time to pVL reaching pre-ART levels in PHI participants
Among the PHI participants, the median (IQR) pre-ART pVL
was 4.5 (3.9, 5.1) log10 copies/ml. Eleven participants had pre-
ART pVL,400 copies/ml and were, therefore, omitted from the
analyses of estimating time to reaching pre-ART pVL. Nine
participants, who had higher median pre-ART pVL (5.5 log10
copies/ml), were censored before reaching pre-ART levels due to
ART re-initiation (one at 5 weeks and the remainder $25 weeks
after ART stop). A total of 71 (42% of 171) participants were
observed to rebound to pre-ART pVL levels, at a median of 50
(95% CI 48, 51) weeks. A quarter of participants had rebounded to
pre-ART levels by 15 (95% CI 12, 26) weeks.
pVL rebound after ART stop by PHI versus chronically-
infected participants
At 4 weeks after ART stop, the proportions with pVL,400
copies/ml were similar in the two groups (Table 2), but median
pVL levels were significantly lower among PHI compared to
chronically-infected participants (unadjusted median 3.7 versus 4.4
log10 copies/ml, respectively; adjusted pVL 0.45 (95% CI 0.26,
0.64) log10 copies/ml lower, p,0.001; Table 3). Higher CD4 cell
count at ART stop was weakly associated with lower week 4 pVL,
and persons infected through heterosexual contact had lower week
4 pVL compared to MSM, but with no evidence that this effect
differed between the PHI and chronically-infected groups (p = 0.4).
There was no association between age at ART stop and week 4
pVL (p = 0.6).
Considering only the chronically-infected participants, pVL was
significantly higher at 4 weeks after ART stop for those on PI-
based or triple NRTI regimens, compared to those on NNRTI-
based regimens (0.69 [0.56,0.81] and 0.58 [0.38,0.79] log10
copies/ml, respectively). There was no evidence of a difference
for other highly-active or suboptimal regimens, compared to
NNRTI-based regimens (0.36 [20.01,0.74] and 0.17
[20.07,0.42] log10 copies/ml, respectively.
Over 48 weeks after ART stop, median pVL remained lower in
individuals with PHI compared to chronically-infected partici-
pants (Figure 1a), with evidence to suggest that chronically-
infected participants rebounded more rapidly than PHI partici-
pants (i.e. had steeper slope; adjusted p,0.0001; Figure 1b).
Predicted pVLs for representative participants are given in
Figure 1b.
The median (IQR) viral burden was 1.12 (0.56, 1.69) and 1.55
(1.03, 1.99) log10 copies/ml amongst PHI and chronically-infected
participants, respectively. After adjustment, viral burden was, on
average, 0.28 (95% CI 0.17, 0.39) log10 copies/ml lower for PHI
versus chronically-infected participants (p,0.001).
The associations between longer-term pVL rebound and sex/
risk group, CD4 cell count and age at ART stop were qualitatively
similar as those for the week 4 pVL rebound (results not shown).
pVL rebound after ART stop, categorising the chronically-
infected participants by nadir CD4 count
Over 4–48 weeks after ART stop, pVL remained significantly
higher in chronically-infected participants with nadir CD4,500
cells/mm3, compared to PHI participants. Lower CD4 nadir was
associated with faster rebound (Figures 2a and 2b). For every 8
weeks the pVL in PHI participants increased, on average, by 0.17
(95% CI 0.14, 0.20) log10 copies/ml compared to 0.15 (0.01, 0.29),
0.33 (0.21, 0.44), 0.46 (0.36, 0.57) and 0.71 (0.60, 0.81) log10
copies/ml in chronically-infected participants with nadir
CD4$500, 350–499, 200–349, and,200 cells/mm3, respectively.
Predicted pVL levels for representative participants are given in
Figure 2b.
We observed a similar relationship for viral burden: chronically-
infected participants with a lower nadir CD4 had higher viral
burden, compared with PHI participants (0.39 [95% CI 0.27,
0.51], 0.29 [0.18, 0.41] and 0.20 [0.06, 0.33] log10 copies/ml
higher viral burden for nadir CD4,200, 200–349 and 350–499
cells/mm3 respectively), but there was no difference in viral
burden between chronically-infected participants with CD4 nadir
$500 cells/mm3 and PHI participants (0.04 [20.12 to 0.20] log10
copies/ml).
HIV Viral Rebound after ART Stop
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The effects of sex/risk group and age at ART stop were similar
to those for week 4 pVL rebound (results not shown). However, we
found evidence of an interaction between nadir CD4 and CD4 cell
count at stop (p = 0.04 and 0.0006 in the linear mixed model for
pVL up to 48 weeks and the linear regression for viral burden,
respectively). CD4 count 100 cells/mm3 higher at ART stop was
associated with a higher viral burden of 0.05 (95% CI 0.03, 0.08)
and 0.02 (20.002, 0.05) log10 copies/ml for chronically-infected
participants with nadir CD4,200 and 200–349 cells/mm3,
respectively. Among chronically-infected participants with nadir
CD4 350–499 or $500 cells/mm3, there was no evidence of such
an association (viral burden 0.002 [20.03, 0.04] and 20.01
[20.05, 0.03] log10 copies/ml higher per 100 cells/mm
3 higher
CD4 at ART stop, respectively). Among PHI participants, there
was evidence to suggest that higher CD4 at ART stop was
associated with lower viral burden (0.04 [95% CI 0.003, 0.08]
log10 copies/ml lower per 100 cells/mm
3 higher CD4 at ART
stop). The effect on viral burden of PHI versus chronic infection/
nadir CD4 remained robust with or without adjustment for CD4
count at ART stop.
Discussion
This is the first study to compare HIV pVL dynamics between
PHI and chronically-infected individuals undergoing a protocol-
indicated ART interruption. We observed that pVL rebound after
stopping ART initiated in PHI was lower than that observed in
chronic infection, at 4 weeks after treatment interruption, and this
Table 1. Participant characteristics at ART stop.
CHRONIC HIV INFECTION PHI (SPARTAC) N=182
(SMART) N=1450
Sex, female (n, %) 350 (24%) 60 (33%)
Age, years (median, IQR) 44 (38, 51) 34 (28, 42)
HIV exposure (n, %)
Sex between men 890 (61%) 114 (63%)
Sex between men & women (male) 222 (15%) 8 (4%)
Sex between men & women (female) 338 (23%) 60 (33%)
Time since first diagnosed HIV positive, months 96 (60, 144) 6 (4, 13)
(median, IQR)
Number of ART drugs, ever (median, IQR) 5 (4, 7) 3 (3, 3)
Number of ART classes, ever (n, %)
1 48 (3%) 0 (0%)
2 763 (53%) 171 (94%)
$3 639 (44%) 11 (6%)
Estimated time on therapy, months (median, IQR) 72 (48, 96) 3 (3, 11)
ART type at stop (n, %)
NNRTI based 674 (46%) 8 (4%)
PI based 521 (36%) 171 (94%)
3 NRTI 132 (9%) 2 (1%)
3 class 84 (6%) 0 (0%)
NRTI sparing 3 (,1%) 0 (0%)
Suboptimal ART 36 (2%) 1 (1%)
Nadir CD4 count up to ART stop, cells/mm3 230 (132, 340) -
(median, IQR; below: n, %)
,200 592 (41%) -
200–349 515 (36%) -
350–499 226 (16%) -
$500 117 (8%) -
CD4 count at ART stop, cells/mm3* (median, 646 (495, 848) 707 (586, 919)
IQR; below: median, IQR by nadir CD4)
nadir CD4,200 cells/mm3 568 (456, 724) -
nadir CD4 200–349 cells/mm3 618 (494, 784) -
nadir CD4 350–499 cells/mm3 806 (646, 993) -
nadir CD4$500 cells/mm3 948 (784, 1176) -
*Closest up to 24 weeks before ART stop. NB: 2 chronically-infected participants had CD4 count ,350 cells/mm3 at ART stop (contrary to SMART inclusion criteria), but
both were measured on the day of ART stop and both participants had previous CD4 count .350 cells/mm3 within the previous 6 weeks.
doi:10.1371/journal.pone.0043754.t001
HIV Viral Rebound after ART Stop
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43754
difference was sustained over 48 weeks of follow-up. In addition,
the overall viral burden, as estimated by the area under the pVL
by time curve, was significantly lower in PHI compared to
chronically-infected participants.
Our findings support those from a smaller study which observed
significantly shorter time to viral rebound following treatment
interruption in participants who initiated treatment in PHI
compared to chronic infection [11]. However, they did not
consider the stage of infection prior to commencing therapy. We
found that, as anticipated, when participants with chronic
infection were stratified by nadir CD4 at time of stopping ART,
lower nadir CD4 was associated with higher pVL after stopping
therapy. Compared to PHI, viral rebound was higher in
chronically-infected participants with nadir CD4,500 cells/
mm3, but similar to levels experienced by those with nadir
CD4$500 cells/mm3. Interestingly, in chronically-infected par-
ticipants with CD4 nadir ,200 cells/mm3, higher CD4 count at
ART stop was associated with subsequent higher viral burden.
Thus, it could be hypothesised that the degree of viral rebound
may be related to the degree of immune reconstitution occurring
during ART, or to the number of CD4 target cells available for
viral infection at ART stop [12].
The observed difference in virological impact of stopping ART
in PHI versus chronic infection may reflect differences in viral
reservoir size although no data were available from either trial on
HIV reservoir size and we were, therefore, unable to directly
examine this. A study of ART initiated during PHI found that 36
Table 2. pVL levels at 4 weeks after ART stop by PHI versus
chronically-infected participants.
pVL, copies/ml Chronic HIV infection PHI (SPARTAC) N=156*
(SMART) N=1327*
,400 284 (21%) 35 (22%)
400–3499 161 (12%) 34 (22%)
3500–9999 110 (8%) 36 (23%)
10,000–49,999 235 (18%) 25 (16%)
$50,000 537 (40%) 26 (17%)
Values are n (%). pVL =plasma viral load.
Adjusted p-value from ordered logistic regression ,0.001.
*Of participants with a week 4 pVL available.
doi:10.1371/journal.pone.0043754.t002
Table 3. Factors associated with pVL level (log10 copies/ml) at 4 weeks after ART stop (from adjusted linear regression model*).
Coefficient (95% CI) P
PHI, versus chronically-infected 20.45 (20.64, 20.26) ,0.001
Age at ART stop, per 10 years 0.01 (20.04, 0.07) 0.6
Sex/risk group, vs men infected through sex with men ,0.001
Male, infected through sex with women 20.14 (20.30, 0.03)
Female, infected through sex with men 20.33 (20.47, 20.20)
CD4 count at ART stop, per 100 cells/mm3 20.02 (20.04, 0.002) 0.08
Constant** 4.26 (4.18, 4.34) -
CI = confidence interval. pVL = plasma viral load. Coefficients are interpreted as the value of log10 copies/ml lower pVL for a negative sign, and higher for a positive sign.
*Adjusted for factors in the table.
**Mean week 4 pVL for a chronically-infected male infected through sex with men, aged 40 years and with CD4 600 cells/mm3 at ART stop.
doi:10.1371/journal.pone.0043754.t003
Figure 1. pVL after ART stop in primary (PHI) and chronic HIV
infection (CHI). a. median (IQR) pVL up to 48 weeks after ART stop. b.
predicted pVL over 4–48 weeks after ART stop, based on a
representative participant (male infected through sex with men, aged
40 years and with CD4 count 600 cells/mm3 at ART stop; values in
brackets are the 95% CI). CI = confidence intervals, IQR = interquartile
range, pLV=plasma viral load.
doi:10.1371/journal.pone.0043754.g001
HIV Viral Rebound after ART Stop
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weeks of therapy reduced proviral HIV-1 DNA to levels
comparable to those seen in long-term non-progressors whilst,
although levels were also reduced in chronic infection, they
remained significantly higher than in PHI and long-term non-
progressors [13]. This was supported by others reporting evidence
for decay of the reservoir in patients who initiated ART early in
infection [14] and a significant reduction in its size in those
initiating ART early, compared to chronic, infection [15].
However, others quantifying the viral reservoir in treated PHI
participants reported that, although a reduction in reservoir size is
observed after even short-course ART initiated in PHI, complete
abolition of viral replication is not achieved and viral reservoir
may be re-expanded even after short-term rebound of viraemia
[16].
As the majority of studies examining short-course ART in PHI
are observational in nature, the reason for starting or stopping
therapy may be related to prognosis. In our analysis, the protocol-
indicated ART cessation in both trial populations minimises the
effect of this potential source of bias, although this study has some
limitations. It was not possible to adjust for ART duration, which
was longer for the chronically-infected compared to PHI
participants, or for ART class. It is also possible that some
SMART participants may have initiated ART in primary
infection, although this information is not captured. Our analyses,
restricted to the chronically-infected participants only, however,
indicated that those previously on NNRTI-based regimens had
lower week 4 pVL rebound compared to those on other regimens.
Since a greater proportion of chronically-infected, compared to
PHI participants, were previously on NNRTI-based regimens,
adjustment for ART class would have only served to augment the
differences reported here between the groups. Longitudinal
analysis of both populations is also subject to bias due to
informative censoring, in particular due to exclusion of data for
individuals who re-initiated ART. However, since a higher
proportion of chronically-infected compared to PHI participants
reinitiated therapy (32% versus 9% before week 48), the results
presented here are likely to be an underestimate of the difference
between the two populations. Although pVL assays varied
according to location, it is unlikely, given the pVL ranges in these
analyses, that use of different commercial pVL assays would
significantly affect the results.
In both trials, pVL was not measured until 4 weeks following
treatment interruption. Although PHI participants were not
observed to rebound to pre-ART pVL levels until a median of
50 weeks, the pVL levels may have been greater before week 4.
Earlier and more frequent testing would give a better indication of
immediate viral dynamics following ART cessation. The move in
the HIV prevention field to explore a universal ‘‘test and treat’’
strategy [9,17–18] is currently receiving much scientific and
advocacy interest. Although mathematical models are encourag-
ing, the effectiveness of such an approach will depend on sustained
adherence to therapy. Transmission risk has been shown to be
higher in those with pVL.1500 copies/ml [5,19]. The data
presented in our analysis show that, irrespective of disease stage
and nadir CD4 count, the level of rebound viraemia on stopping
ART in the vast majority of individuals reaches a level above
which transmission can occur. Targeting individuals with ART
during PHI could have a marked impact on HIV transmission
[20], but it is crucial that strategies investigating the use of ART as
transmission prevention examine the consequences of ART
discontinuation and viral rebound on onward transmission. In
addition to the impact of pVL on transmission, the sexual
behaviour of those individuals critically impacts their transmission
risk at a population level [21]. In the SMART trial, individuals did
not reduce high-risk sexual behaviour despite treatment interrup-
tion and detectable pVL [22]. This was not investigated in
SPARTAC. However, in a recent study looking at onward HIV
transmission amongst 47 individuals treated in PHI who stopped
ART, there were at least five new primary infection events
originating from these persons within 16–61 weeks after stopping
early ART [23].
This analysis provides estimates for the viral rebound following
cessation of ART initiated in PHI or chronic infection, and may
inform mathematical models evaluating the potential population
effect of universal treatment on HIV incidence for individuals
stopping ART. The demonstrated differences in viral load
dynamics following ART cessation between PHI and chronic
infection indicate that the consequences of treatment interruption
may differ, potentially reflecting differences in immunological
status, HIV activation and reservoir size. This analysis supports
Figure 2. pVL after ART stop in primary (PHI) and chronic HIV
infection (CHI), with CHI participants categorised by nadir CD4
count. a. median (IQR) pVL up to 48 weeks after ART stop. b. predicted
pVL over 4–48 weeks after ART stop, based on a representative
participant (male infected through sex between men, aged 40 years
and CD4 count 600 cells/mm3 at ART stop; values in brackets are the
95% CI). CI = confidence intervals, IQR = interquartile range,
pLV =plasma viral load.
doi:10.1371/journal.pone.0043754.g002
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the necessity for sustained virological suppression to limit onward
transmission risk if a ‘‘test and treat’’ approach is to deliver a
sustained population level effect on HIV incidence.
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